Naked plasmid DNA-based α-galactosidase a gene transfer partially reduces systemic accumulation of globotriaosylceramide in Fabry mice

Molecular Biotechnology

Volumn 38, Issue 2, 2008, Pages 109-119

  Nakamura, Gen ^a   Maruyama, Hiroki ^a   Ishii, Satoshi ^b   Shimotori, Masaaki ^a   Kameda, Shigemi ^a   Kono, Toru ^c   Miyazaki, Jun Ichi ^d   Kulkarni, Ashok B ^e   Gejyo, Fumitake ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b OBIHIRO UNIVERSITY OF AGRICULTURE AND VETERINARY MEDICINE   (Japan)

^c ASAHIKAWA MEDICAL COLLEGE   (Japan)

^d OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^e NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

CAG promoter; Catheter based gene transfer; Fabry disease; Hydrodynamics based transfection; Naked plasmid DNA; Renal vein injection

Indexed keywords

DNA; FOOD ADDITIVES; GENES; GENETIC ENGINEERING; HEALTH; LIVER; NUCLEIC ACIDS; ORGANIC ACIDS; VECTORS;

CAG PROMOTER; CATHETER-BASED GENE TRANSFER; FABRY DISEASE; GALACTOSIDASE; GENE THERAPIES; GLOBOTRIAOSYLCERAMIDE; HYDRODYNAMICS-BASED TRANSFECTION; KNOCK-OUT; METABOLIC DISORDERS; NAKED DNA; NAKED PLASMID; NAKED PLASMID DNA; RENAL VEIN; RENAL VEIN INJECTION; REVERSE TRANSCRIPTASE- POLYMERASE CHAIN REACTION; TRANSFER TECHNIQUE;

GENE TRANSFER;

ALPHA GALACTOSIDASE; GLOBOTRIAOSYLCERAMIDE; IMMUNOGLOBULIN G ANTIBODY; MESSENGER RNA; NAKED DNA; PLASMID DNA; PLASMID VECTOR; ANTIBODY; CERAMIDE TRIHEXOSIDE; DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY GROWTH; BODY WEIGHT; BRAIN; CELL STRAIN COS7; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME ANALYSIS; FABRY DISEASE; FEMALE; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC TRANSFECTION; HEART; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; KIDNEY; LIVER; MALE; MOUSE; MUSCLE; NONHUMAN; PLASMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN; SMALL INTESTINE; SPLEEN; TISSUE LEVEL; ANIMAL; ANTIBODY SPECIFICITY; CELL STRAIN COS1; CERCOPITHECUS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; PLASMID; TRANSGENE;

MUS;

ALPHA-GALACTOSIDASE; ANIMALS; ANTIBODIES; BODY WEIGHT; CERCOPITHECUS AETHIOPS; COS CELLS; DNA; FABRY DISEASE; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MALE; MICE; ORGAN SPECIFICITY; PLASMIDS; RNA, MESSENGER; TRANSGENES; TRIHEXOSYLCERAMIDES;

EID: 42449097323     PISSN: 10736085     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12033-007-9008-5     Document Type: Article

References (40)

1. Desnick R. J., Ionnou Y. A., & Eng C. M. (2001). α- Galactosidase A deficiency: Fabry disease, In Scriver C. R., Beaudet A. L., Sly W. S., & Valle D., Eds., The metabolic and molecular bases of inherited disease, 8th ed. (pp. 3733-3774). New York: McGraw-Hill.
2. R. O. Brady A. E. Gal R. M. Bradley E. Martensson A. L. Warshaw L. Laster 1967 Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency New England Journal of Medicine 276 1163 1167
3. M. C. Marguery F. Giordano M. Parant G. Samalens T. Levade R. Salvayre A. Maret P. Calvas G. Bourrouillou P. Cantala 1993 Fabry's disease: Heterozygous form of different expression in two monozygous twin sisters Dermatology 187 9 15
4. C. Whybra C. Kampmann I. Willers J. Davies B. Winchester J. Kriegsmann K. Bruhl A. Gal S. Bunge M. Beck 2001 Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes Journal of Inherited Metabolic Disease 24 715 724
5. H. Takahashi Y. Hirai M. Migita Y. Seino Y. Fukuda H. Sakuraba R. Kase T. Kobayashi Y. Hashimoto 2002 Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer Proceedings of the National Academy of Sciences of the United States of America 99 13777 13782
6. J. H. Wolfe M. S. Sands J. E. Barker B. Gwynn L. B. Rowe C. A. Vogler E. H. Birkenmeier 1992 Reversal of pathology in murine mucopolysaccharidosis type VII by somatic cell gene transfer Nature 360 749 753
7. S. Ishii R. Kase H. Sakuraba 1995 The functional role of glutamine-280 and threonine-282 in human alpha-galactosidase Biochimica et Biophysica Acta 1270 163 167
8. R. J. Ziegler C. Li M. Cherry Y. Zhu D. Hempel N. van Rooijen Y. A. Ioannou R. J. Desnick M. A. Goldberg N. S. Yew S. H. Cheng 2002 Correction of the nonlinear dose response improves the viability of adenoviral vectors for gene therapy of Fabry disease Human Gene Therapy 13 935 945
9. S. C. Jung I. P. Han A. Limaye R. Xu M. P. Gelderman P. Zerfas K. Tirumalai G. J. Murray M. J. During R. O. Brady P. Qasba 2001 Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice Proceedings of the National Academy of Sciences of the United States of America 98 2676 2681
10. R. J. Ziegler S. M. Lonning D. Armentano C. Li D. W. Souza M. Cherry C. Ford C. M. Barbon R. J. Desnick G. Gao J. M. Wilson R. Peluso S. Godwin B. J. Carter R. J. Gregory S. C. Wadworth S. H. Cheng 2004 AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry mice Molecular Therapy 9 231 240
11. C. Li R. J. Ziegler M. Cherry R. J. Desnick N. S. Yew S. H. Cheng 2002 Adenovirus-transduced lung as a portal for delivering alpha-galactosidase A into systemic circulation for Fabry disease Molecular Therapy 5 745 754
12. M. Przybylska I. H. Wu H. Zhao R. J. Ziegler J. D. Tousignant R. J. Desnick R. K. Scheule S. H. Cheng N. S. Yew 2004 Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors Journal of Gene Medicine 6 85 92
13. M. Yoshimitsu T. Sato K. Tao J. S. Walia V. I. Rasaiah G. T. Sleep G. J. Murray A. G. Poeppl J. Underwood L. West R. O. Brady J. A. Medin 2004 Bioluminescent imaging of a marking transgene and correction of Fabry mice by neonatal injection of recombinant lentiviral vectors Proceedings of the National Academy of Sciences of the United States of America 101 16909 16914
14. J. Park G. J. Murray A. Limaye J. M. Quirk M. P. Gelderman R. O. Brady P. Qasba 2003 Long-term correction of globotriaosylceramide storage in Fabry mice by recombinant adeno-associated virus-mediated gene transfer Proceedings of the National Academy of Sciences of the United States of America 100 3450 3454
15. R. J. Ziegler N. S. Yew C. Li M. Cherry P. Berthelette H. Romanczuk Y. A. Ioannou K. M. Zeidner R. J. Desnick S. H. Cheng 1999 Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer Human Gene Therapy 10 1667 1682
16. M. D. Lavigne M. Pohlschmidt J. F. Novo B. Higgins V. Alakhov H. Lochmuller H. Sakuraba G. Goldspink K. MacDermot D. C. Gorecki 2005 Promoter dependence of plasmid-pluronics targeted alpha galactosidase A expression in skeletal muscle of Fabry mice Molecular Therapy 12 985 990
17. M. Branton R. Schiffmann J. B. Kopp 2002 Natural history and treatment of renal involvement in Fabry disease Journal of the American Society of Nephrology 13 Suppl 2 139 143
18. M. H. Branton R. Schiffmann S. G. Sabnis G. J. Murray J. M. Quirk G. Altarescu L. Goldfarb R. O. Brady J. E. Balow H. A. Austin III J. B. Kopp 2002 Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course Medicine 81 122 138
19. H. Maruyama N. Higuchi Y. Nishikawa H. Hirahara N. Iino S. Kameda H. Kawachi E. Yaoita F. Gejyo J. Miyazaki 2002 Kidney-targeted naked DNA transfer by retrograde renal vein injection in rats Human Gene Therapy 13 455 468
20. S. Kameda H. Maruyama N. Higuchi N. Iino G. Nakamura J. Miyazaki F. Gejyo 2004 Kidney-targeted naked DNA transfer by retrograde injection into the renal vein in mice Biochemical and Biophysical Research Communications 314 390 395
21. H. Niwa K. Yamamura J. Miyazaki 1991 Efficient selection for high-expression transfectants with a novel eukaryotic vector Gene 108 193 199
22. H. Maruyama M. Sugawa Y. Moriguchi I. Imazeki Y. Ishikawa K. Ataka S. Hasegawa Y. Ito N. Higuchi J. J. Kazama F. Gejyo J. Miyazaki 2000 Continuous erythropoietin delivery by muscle-targeted gene transfer using in vivo electroporation Human Gene Therapy 11 429 437
23. S. Ishii R. Kase H. Sakuraba S. Fujita M. Sugimoto K. Tomita T. Semba Y. Suzuki 1994 Human alpha-galactosidase gene expression: significance of two peptide regions encoded by exons 1-2 and 6 Biochimica et Biophysica Acta 1204 265 270
24. T. Ohshima G. J. Murray W. D. Swaim G. Longenecker J. M. Quirk C. O. Cardarelli Y. Sugimoto I. Pastan M. M. Gottesman R. O. Brady A. B. Kulkarni 1997 Alpha-galactosidase A deficient mice: A model of Fabry disease Proceedings of the National Academy of Sciences of the United States of America 94 2540 2544
25. S. Ishii H. Yoshioka K. Mannen A. B. Kulkarni J. Q. Fan 2004 Transgenic mouse expressing human mutant alpha-galactosidase A in an endogenous enzyme deficient background: A biochemical animal model for studying active-site specific chaperone therapy for Fabry disease Biochimica et Biophysica Acta 1690 250 257
26. J. Q. Fan S. Ishii N. Asano Y. Suzuki 1999 Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor Nature Medicine 5 112 115
27. J. S. Mayes J. B. Scheerer R. N. Sifers M.L. Donaldson 1981 Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry's disease Clinica Chimica Acta. 112 245 251
28. R. H. McCluer M. A. Williams S. K. Gross M. H. Meisler 1981 Testosterone effects on the induction and urinary excretion of mouse kidney glycosphingolipids associated with lysosomes Journal of Biological Chemistry 256 13112 13120
29. Pharmaceuticals and Medical Devices Agency for Evaluation of Medicinal Products. January 2004, http://www.info.pmda.go.jp/shinyaku/g040106/index.html? submit=%C9%BD%BC%A8.
30. Y. A. Ioannou K. M. Zeidner R. E. Gordon R. J. Desnick 2001 Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice American Journal of Human Genetics 68 14 25
31. R. O. Brady G. J. Murray D. F. Moore R. Schiffmann 2001 Enzyme replacement therapy in Fabry disease Journal of Inherited Metabolic Disease 24 Suppl 2 18 24
32. K. Lee X. Jin K. Zhang L. Copertino L. Andrews J. Baker-Malcolm L. Geagan H. Qiu K. Seiger D. Barngrover J. M. McPherson T. Edmunds 2003 A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease Glycobiology 13 305 313
33. P. E. R. J. Monahan Samulski 2000 Adeno-associated virus vectors for gene therapy: More pros than cons? Molecular Medicine Today 6 433 440
34. N. Chirmule K. Propert S. Magosin Y. Qian R. Qian J. Wilson 1999 Immune responses to adenovirus and adeno-associated virus in humans Gene Therapy 6 1574 1583
35. S. C. D. N. Garman Garboczi 2004 The molecular defect leading to Fabry disease: structure of human alpha-galactosidase Journal of Molecular Biology 337 319 335
36. R. Schiffmann J. B. Kopp H. A. Austin S. Sabnis D. F. Moore T. Weibel J. E. Balow R. O. Brady 2001 Enzyme replacement therapy in Fabry disease: a randomized controlled trial JAMA-Journal of the American Medical Association 285 2743 2749
37. A. S. Stern M. E. Klotman Y. A. Ioannou C. R. Burrow P. D. Wilson P. E. Klotman M. S. Lipkowitz 2002 Polarity of alpha-galactosidase A uptake by renal tubule cells Kidney International 61 Suppl 1 52 55
38. B. L. Thurberg H. Rennke R. B. Colvin S. Dikman R. E. Gordon A. B. Collins R. J. Desnick M. O'callaghan 2002 Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy Kidney International 62 1933 1946
39. Maddox D. A. & Brenner, B. M. (2000). Glomerular ultrafiltration, in Elements of normal renal structure and function, vol. 1. In Brenner B. M. (Ed.), Brenner & Rector's The kidney 7th ed. (pp. 353-412). Philadelphia: WB Saunders.
40. P. Ye A. R. Thompson R. Sarkar Z. Shen D. P. Lillicrap R. J. Kaufman H. D. Ochs D. J. Rawlings C. H. Miao 2004 Naked DNA transfer of Factor VIII induced transgene-specific, species-independent immune response in hemophilia A mice Molecular Therapy 10 117 126